Deferasirox Articles
FDA clears new use for Roche's Avastin and Novartis' Exjade
25 January 2013
News briefs from Sanofi, Bayer, GlaxoSmithKline and Novartis
21 December 2012
More news briefs from ASH meeting
14 December 2011
US FDA warns on renal, hepatic and gastro problems with Novartis’ Exjade; clears Roche/Biogen’s Rituxan for CLL
19 February 2010
Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes
26 January 2010
Novartis' 1st-qtr 2009 results boosted by new products
24 April 2009
ASH hears strong data on Novartis
22 December 2008
Exjade effective against transfusion iron overload
15 December 2008
Exjade cuts thalassemia iron build up in organs
20 October 2008
Japan drug approval recommendations
11 February 2008
Exjade cuts high iron levels in b-thalassemia
17 December 2007
Novartis sends out Dear Doctor letter for Exjade
28 May 2007
Novartis' Exjade approved in Scotland
19 February 2007
Novartis' Exjade approved in Scotland
19 February 2007
Novartis' Exjade approved in the UK
2 October 2006
Novartis' Exjade approved by EC
4 September 2006
Industry bodies oppose annual revision of Japan
7 August 2006
CHMP Update on current activities
10 July 2006
Novartis sees strong performance with record results in 2005
30 January 2006
Priority review for Novartis' Exjade
27 June 2005
Novartis files Exjade in USA and EU
9 May 2005
Novartis shows off strong R&D pipeline at annual conference
31 January 2005
Showing 1-29 of 29 articles
- 1
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- SciClone gains China rights to Zensun's Neucardin
